每年研究成果
每年研究成果
個人檔案
學歷
- 國立成功大學醫學系學士
經歷
- 2018年08月 ~迄今 胸腔內科醫師
- 2013年08月 ~2018年07月 內科部住院醫師
指紋
查看啟用 Chian-Wei Chen 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
- 1 類似的個人檔案
網路
國家/地區層面的近期外部共同作業。按一下圓點深入探索詳細資料，或
-
Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study
Huang, T. H., Kuo, C. W., Chen, C. W., Tseng, Y. L., Wu, C. L. & Lin, S. H., 2021 十二月, 於: BMC Pulmonary Medicine. 21, 1, 165.研究成果: Article › 同行評審
開啟存取2 引文 斯高帕斯（Scopus） -
Correction to: Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study (BMC Pulmonary Medicine, (2021), 21, 1, (165), 10.1186/s12890-021-01530-6)
Huang, T. H., Kuo, C. W., Chen, C. W., Tseng, Y. L., Wu, C. L. & Lin, S. H., 2021 十二月, 於: BMC Pulmonary Medicine. 21, 1, 193.研究成果: Comment/debate › 同行評審
開啟存取 -
First-line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation-positive non-small cell lung cancer
Su, P. L., Chen, C. W., Wu, Y. L., Lin, C. C. & Su, W. C., 2021 二月, 於: Thoracic Cancer. 12, 3, p. 287-296 10 p.研究成果: Article › 同行評審
開啟存取1 引文 斯高帕斯（Scopus） -
Improved survival in patients with unresectable stage III EGFR-mutant adenocarcinoma with upfront EGFR-tyrosine kinase inhibitors
Wang, S. Y., Lai, C. H., Chen, C. W., Yang, S. C., Chang, C. C., Lin, C. Y., Yen, Y. T., Tseng, Y. L., Su, P. L., Lin, C. C. & Su, W. C., 2021, (Accepted/In press) 於: Thoracic Cancer.研究成果: Article › 同行評審
開啟存取 -
Successful AZD9291 Therapy in Advanced Non–Small Cell Lung Cancer after Failure of HM61713
Chen, C. W., Kuo, C. W., Chen, Y. L., Ho, C. L., Su, W. C. & Lin, C. C., 2017 六月, 於: Journal of Thoracic Oncology. 12, 6, p. e72-e74研究成果: Letter › 同行評審
3 引文 斯高帕斯（Scopus）